Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus

Helena Enocsson*, Lina Wirestam, Charlotte Dahle, Leonid Padyukov, Andreas Jönsen, Murray B. Urowitz, Dafna D. Gladman, Juanita Romero-Diaz, Sang Cheol Bae, Paul R. Fortin, Jorge Sanchez-Guerrero, Ann E. Clarke, Sasha Bernatsky, Caroline Gordon, John G. Hanly, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Ellen GinzlerGraciela S. Alarcón, W. Winn Chatham, Michelle Petri, Munther Khamashta, Cynthia Aranow, Meggan Mackay, Mary Anne Dooley, Susan Manzi, Rosalind Ramsey-Goldman, Ola Nived, Kristjan Steinsson, Asad A. Zoma, Guillermo Ruiz-Irastorza, S. Sam Lim, Kenneth C. Kalunian, Murat Inanc, Ronald F. van Vollenhoven, Manuel Ramos-Casals, Diane L. Kamen, Søren Jacobsen, Christine A. Peschken, Anca Askanase, Thomas Stoll, Ian N. Bruce, Jonas Wetterö, Christopher Sjöwall

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Objective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE. Methods: Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI). Results: The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03–1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007). Conclusion: Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.

Original languageEnglish (US)
Article number102340
JournalJournal of Autoimmunity
Volume106
DOIs
StatePublished - Jan 2020

    Fingerprint

Keywords

  • Biomarker
  • Organ damage
  • Outcome
  • Prognosis
  • SLE

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Enocsson, H., Wirestam, L., Dahle, C., Padyukov, L., Jönsen, A., Urowitz, M. B., Gladman, D. D., Romero-Diaz, J., Bae, S. C., Fortin, P. R., Sanchez-Guerrero, J., Clarke, A. E., Bernatsky, S., Gordon, C., Hanly, J. G., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., ... Sjöwall, C. (2020). Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 106, [102340]. https://doi.org/10.1016/j.jaut.2019.102340